Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus PEDIAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus PEDIAPRED.
CORTIFOAM vs PEDIAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Category C
Category C
Corticosteroid
Corticosteroid